Protection from Systemic Candida albicans infection by inactivation of the sts phosphatases

Infection and Immunity

Volumn 83, Issue 2, 2015, Pages 637-645

  Naseem, Shamoon ^a   Frank, David ^a   Konopka, James B ^a   Carpino, Nick ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; PHOSPHATASE; STS PHOSPHATASE; UNCLASSIFIED DRUG; LYMPHOCYTE ANTIGEN RECEPTOR; STS-1 PROTEIN, MOUSE; STS-2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; FUNGUS GROWTH; HEMATOPOIETIC CELL; IMMUNE RESPONSE; INFECTION RESISTANCE; INVASIVE CANDIDIASIS; LETHALITY; MAST CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; THROMBOCYTE; ANIMAL; C57BL MOUSE; CANDIDIASIS; GENETICS; IMMUNOLOGY; KIDNEY; KNOCKOUT MOUSE; MICROBIOLOGY;

ANIMALS; CANDIDA ALBICANS; CANDIDIASIS; KIDNEY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, ANTIGEN, T-CELL;

EID: 84921364732     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.02789-14     Document Type: Article

References (39)

1. Pfaller MA, Diekema DJ. 2010. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 36:1-53. http://dx.doi.org/10.3109/10408410903241444.
2. Lionakis MS. 2014. New insights into innate immune control of systemic candidiasis. Med Mycol 52:555-564. http://dx.doi.org/10.1093/mmy/myu029.
3. Mayer FL, Wilson D, Hube B. 2013. Candida albicans pathogenicity mechanisms. Virulence 4:119-128. http://dx.doi.org/10.4161/viru.22913.
4. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. 2012. Hidden killers: human fungal infections. Sci Transl Med 4:165rv13. http://dx.doi.org/10.1126/scitranslmed.3004404.
5. van de Veerdonk FL, Kullberg BJ, Netea MG. 2010. Pathogenesis of invasive candidiasis. Curr Opin Crit Care 16:453-459. http://dx.doi.org/10.1097/MCC.0b013e32833e046e.
6. Brown GD, Denning DW, Levitz SM. 2012. Tackling human fungal infections. Science 336:647. http://dx.doi.org/10.1126/science.1222236.
7. Ashman RB. 1997. Genetic determination of susceptibility and resistance in the pathogenesis of Candida albicans infection. FEMS Immunol Med Microbiol 19:183-189. http://dx.doi.org/10.1111/j.1574-695X.1997.tb01087.x.
8. Lionakis MS, Lim JK, Lee CC, Murphy PM. 2011. Organ-specific innate immune responses in a mouse model of invasive candidiasis. J Innate Immun 3:180-199. http://dx.doi.org/10.1159/000321157.
9. Brown GD. 2011. Innate antifungal immunity: the key role of phagocytes. Annu Rev Immunol 29:1-21. http://dx.doi.org/10.1146/annurev-immunol-030409-101229.
10. Cheng SC, Joosten LA, Kullberg BJ, Netea MG. 2012. Interplay between Candida albicans and the mammalian innate host defense. Infect Immun 80:1304-1313. http://dx.doi.org/10.1128/IAI.06146-11.
11. Majer O, Bourgeois C, Zwolanek F, Lassnig C, Kerjaschki D, Mack M, Muller M, Kuchler K. 2012. Type I interferons promote fatal immunopathology by regulating inflammatory monocytes and neutrophils during Candida infections. PLoS Pathog 8:e1002811. http://dx.doi.org/10.1371/journal.ppat.1002811.
12. Spellberg B, Ibrahim AS, Edwards JE, Jr, Filler SG. 2005. Mice with disseminated candidiasis die of progressive sepsis. J Infect Dis 192:336- 343. http://dx.doi.org/10.1086/430952.
13. Perlin DS. 2009. Antifungal drug resistance: do molecular methods provide a way forward? Curr Opin Infect Dis 22:568-573. http://dx.doi.org/10.1097/QCO.0b013e3283321ce5.
14. Kullberg BJ, Verweij PE, Akova M, Arendrup MC, Bille J, Calandra T, Cuenca-Estrella M, Herbrecht R, Jacobs F, Kalin M, Kibbler CC, Lortholary O, Martino P, Meis JF, Munoz P, Odds FC, De Pauw BE, Rex JH, Roilides E, Rogers TR, Ruhnke M, Ullmann AJ, Uzun O, Vandewoude K, Vincent JL, Donnelly JP. 2011. European expert opinion on the management of invasive candidiasis in adults. Clin Microbiol Infect 17(Suppl 5):S1- S12. http://dx.doi.org/10.1111/j.1469-0691.2011.03557.x.
15. CDC. 2013. Antibiotic resistance threats in the United States, 2013. CDC, Atlanta, GA. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf.
16. Armstrong-James D, Harrison TS. 2012. Immunotherapy for fungal infections. Curr Opin Microbiol 15:434-439. http://dx.doi.org/10.1016/j.mib.2012.06.001.
17. van de Veerdonk FL, Kullberg BJ, Netea MG. 2012. Adjunctive immunotherapy with recombinant cytokines for the treatment of disseminated candidiasis. Clin Microbiol Infect 18:112-119. http://dx.doi.org/10.1111/j.1469-0691.2011.03676.x.
18. Spellberg B. 2011. Vaccines for invasive fungal infections. F1000 Med Rep 3:13. http://dx.doi.org/10.3410/M3-13.
19. Filler SG. 2013. Can host receptors for fungi be targeted for treatment of fungal infections? Trends Microbiol 21:389-396. http://dx.doi.org/10.1016/j.tim.2013.05.006.
20. Carpino N, Turner S, Mekala D, Takahashi Y, Zang H, Geiger TL, Doherty P, Ihle JN. 2004. Regulation of ZAP-70 activation and TCR signaling by two related proteins, Sts-1 and Sts-2. Immunity 20:37-46. http://dx.doi.org/10.1016/S1074-7613(03)00351-0.
21. Thomas DH, Getz TM, Newman TN, Dangelmaier CA, Carpino N, Kunapuli SP, Tsygankov AY, Daniel JL. 2010. A novel histidine tyrosine phosphatase, TULA-2, associates with Syk and negatively regulates GPVI signaling in platelets. Blood 116:2570-2578. http://dx.doi.org/10.1182/blood-2010-02-268136.
22. de Castro RO, Zhang J, Groves JR, Barbu EA, Siraganian RP. 2012. Once phosphorylated, tyrosines in carboxyl terminus of protein-tyrosine kinase Syk interact with signaling proteins, including TULA-2, a negative regulator of mast cell degranulation. J Biol Chem 287:8194-8204. http://dx.doi.org/10.1074/jbc.M111.326850.
23. Tsygankov AY. 2013. TULA-family proteins: a new class of cellular regulators. J Cell Physiol 228:43-49. http://dx.doi.org/10.1002/jcp.24128.
24. Mikhailik A, Ford B, Keller J, Chen Y, Nassar N, Carpino N. 2007. A phosphatase activity of Sts-1 contributes to the suppression of TCR signaling. Mol Cell 27:486-497. http://dx.doi.org/10.1016/j.molcel.2007.06.015.
25. San Luis B, Sondgeroth B, Nassar N, Carpino N. 2011. Sts-2 is a phosphatase that negatively regulates zeta-associated protein (ZAP)-70 and T cell receptor signaling pathways. J Biol Chem 286:15943-15954. http://dx.doi.org/10.1074/jbc.M110.177634.
26. Cieniewicz B, Carpino N, Krug LT. 2014. Enhanced response of T cells from murine gammaherpesvirus 68-infected mice lacking the suppressor of T cell receptor signaling molecules Sts-1 and Sts-2. PLoS One 9:e90196. http://dx.doi.org/10.1371/journal.pone.0090196.
27. Douglas LM, Wang HX, Keppler-Ross S, Dean N, Konopka JB. 2012. Sur7 promotes plasma membrane organization and is needed for resistance to stressful conditions and to the invasive growth and virulence of Candida albicans. mBio 3(1):e00254-11. http://dx.doi.org/10.1128/mBio.00254-11.
28. Ngo LY, Kasahara S, Kumasaka DK, Knoblaugh SE, Jhingran A, Hohl TM. 2014. Inflammatory monocytes mediate early and organ-specific innate defense during systemic candidiasis. J Infect Dis 209:109-119. http://dx.doi.org/10.1093/infdis/jit413.
29. Ashman RB, Papadimitriou JM. 1995. Production and function of cytokines in natural and acquired immunity to Candida albicans infection. Microbiol Rev 59:646-672.
30. MacCallum DM, Castillo L, Brown AJ, Gow NA, Odds FC. 2009. Early-expressed chemokines predict kidney immunopathology in experimental disseminated Candida albicans infections. PLoS One 4:e6420. http://dx.doi.org/10.1371/journal.pone.0006420.
31. Lionakis MS, Fischer BG, Lim JK, Swamydas M, Wan W, Richard Lee CC, Cohen JI, Scheinberg P, Gao JL, Murphy PM. 2012. Chemokine receptor Ccr1 drives neutrophil-mediated kidney immunopathology and mortality in invasive candidiasis. PLoS Pathog 8:e1002865. http://dx.doi.org/10.1371/journal.ppat.1002865.
32. Mahanty S, Greenfield RA, Joyce WA, Kincade PW. 1988. Inoculation candidiasis in a murine model of severe combined immunodeficiency syndrome. Infect Immun 56:3162-3166.
33. Lacotte S, Brun S, Muller S, Dumortier H. 2009. CXCR3, inflammation, and autoimmune diseases. AnnNY Acad Sci 1173:310-317. http://dx.doi.org/10.1111/j.1749-6632.2009.04813.x.
34. Antonelli A, Ferrari SM, Giuggioli D, Ferrannini E, Ferri C, Fallahi P. 2014. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev 13:272-280. http://dx.doi.org/10.1016/j.autrev.2013.10.010.
35. Groom JR, Luster AD. 2011. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 89:207-215. http://dx.doi.org/10.1038/icb.2010.158.
36. Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO, Stiles JK. 2011. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev 22:121-130. http://dx.doi.org/10.1016/j.cytogfr.2011.06.001.
37. van Spriel AB, Sofi M, Gartlan KH, van der Schaaf A, Verschueren I, Torensma R, Raymakers RA, Loveland BE, Netea MG, Adema GJ, Wright MD, Figdor CG. 2009. The tetraspanin protein CD37 regulates IgA responses and anti-fungal immunity. PLoS Pathog 5:e1000338. http://dx.doi.org/10.1371/journal.ppat.1000338.
38. Meyer-Wentrup F, Figdor CG, Ansems M, Brossart P, Wright MD, Adema GJ, van Spriel AB. 2007. Dectin-1 interaction with tetraspanin CD37 inhibits IL-6 production. J Immunol 178:154-162. http://dx.doi.org/10.4049/jimmunol.178.1.154.
39. Rops AL, Figdor CG, van der Schaaf A, Tamboer WP, Bakker MA, Berden JH, Dijkman HB, Steenbergen EJ, van der Vlag J, van Spriel AB. 2010. The tetraspanin CD37 protects against glomerular IgA deposition and renal pathology. Am J Pathol 176:2188-2197. http://dx.doi.org/10.2353/ajpath.2010.090770.